Bala: Evidence, Safety & Traditional Uses

Q: What is bala?

Bala is Sida cordifolia L., a mallowfamily herb used in Ayurveda as a strengthening tonic (rasayana) for respiratory, inflammatory, and neurological complaints (Tailor 2026:AComprehensiveReviewofitsEthnobotany,Phytochemistry,andPharmacology.pdf)). Its roots contain stimulant ephedrinetype alkaloids, though the exact ephedrine content is disputed (JiménezFerrer et al., Plants 2025). My short version: classical tonic, stimulant chemistry, thin human evidence.

TL;DR

Bala (Sida cordifolia) is an Ayurvedic tonic herb with no verified human-trial record as a single herb: the one identifiable randomized trial combined it with Phyllanthus niruri, and a separate tabulated knee-arthritis study has no identifiable primary paper. Animal work shows anti-inflammatory effects, but its ephedrine-type alkaloids fall under the FDA's 2004 supplement rule.

That is a strange combination, and it is why this article exists. On one hand, a respected classical tonic with centuries of traditional use. On the other, a plant whose chemistry overlaps with a stimulant class the US FDA declared an unreasonable risk in dietary supplements. My job here is to keep both facts in your head at once, and to be honest about a third: the human evidence for bala is so thin that almost everything written about its benefits is extrapolation.

What it is

Bala is Sida cordifolia L., a member of the mallow family (Malvaceae). The genus Sida includes roughly 200 species found in tropical and subtropical regions worldwide. Bala itself is an annual or perennial herb to subshrub, 0.5 to 2.0 m tall, with small cream, yellow, pink, or purplish flowers (Jiménez-Ferrer et al., Plants 2025). In Ayurvedic medicine it is known simply as Bala (Tailor, Mathews J Pharma Sci 2026:_A_Comprehensive_Review_of_its_Ethnobotany,_Phytochemistry,_and_Pharmacology.pdf)).

Its chemistry is dominated by alkaloids, and here is where I need you to pay attention. A water-soluble alkaloid fraction from the roots yielded ψ-ephedrine (pseudoephedrine) (Jiménez-Ferrer et al., Plants 2025). Pseudoephedrine is a known sympathomimetic: it stimulates alpha-adrenergic receptors, increasing breathing rate and blood pressure, accelerating heart rate, dilating the bronchi, raising blood glucose, stimulating the central nervous system, and producing a sense of increased energy. That is a stimulant profile, full stop. But a 2026 comprehensive review cautions that the presence of the alkaloid ephedrine itself in the plant "remains a subject of significant scientific controversy, with conflicting reports in the literature" (Tailor 2026:_A_Comprehensive_Review_of_its_Ethnobotany,_Phytochemistry,_and_Pharmacology.pdf)). So stimulant content varies and is disputed. Products are not interchangeable, and anyone who treats them as a uniform "natural tonic" is ignoring the chemistry.

Traditional use

In Ayurveda, bala is traditionally employed as a strengthening tonic (rasayana), used for a wide array of ailments including respiratory conditions, inflammatory disorders, and neurological diseases (Tailor 2026:_A_Comprehensive_Review_of_its_Ethnobotany,_Phytochemistry,_and_Pharmacology.pdf)). Across the Sida genus, folk-medicine history includes use for inflammation, pain, and nervousness (Jiménez-Ferrer et al., Plants 2025). These are traditional indications. I say it every time because it matters: traditional use is not clinical proof, and the human evidence gets examined separately below.

What modern research says

Arthritis (human-trial record)

The 2025 Sida review tabulates one poorly detailed knee-osteoarthritis study of an Ayurvedic medicated-milk preparation. The review does not report the trial's design, the primary paper is not identified, and no clinical-trial result or regimen can be stated here. The one identifiable randomized trial of a bala-containing regimen (Patel et al., 2022, covered in the Voices section below) combined bala with Phyllanthus niruri, so its result cannot be attributed to bala alone. A tabulated mention in a review is not evidence you can act on. It is a lead for researchers, nothing more.

Inflammation and pain (animal studies)

In a 2000 study in the Journal of Ethnopharmacology, an aqueous leaf extract of S. cordifolia at 400 mg/kg given orally significantly inhibited carrageenan-induced paw edema in rats, increased hot-plate latency in mice, and reduced acetic-acid-induced writhing (Franzotti et al., J Ethnopharmacol 2000). Those are animal models of inflammation and pain, and the extract showed low acute toxicity in mice. Interesting? Sure. Human evidence? Not even close. Animal findings do not establish human efficacy, and a leaf extract in rodents says nothing about what a root powder does in people.

What the evidence does not support (yet)

No human trial of bala alone has been identified for its traditional respiratory, neurological, or general tonic uses. The one identifiable randomized trial of a bala-containing regimen (Patel et al., 2022, in diabetic sensory polyneuropathy) combined it with Phyllanthus niruri, so it tests a combination, not bala by itself. The review's tabulated pharmacological activities (antioxidant, sedative, hepatoprotective, and others) come from preclinical work, and the authors emphasize that rigorous chemical-pharmacological studies are still scarce (Jiménez-Ferrer et al., Plants 2025). So the traditional reputation is large and the verified human evidence for bala as a single herb is, to put it bluntly, one unidentified tabulated study.

Dosage

No standard dose can be stated. No single-herb regimen can be given here, because the one identifiable human trial of a bala-containing regimen (Patel 2022) used a two-herb combination. Because stimulant-alkaloid content varies between plant parts and preparations, and is itself disputed, products are not interchangeable. Do not self-dose; consult a qualified practitioner. I am firm on this one: guessing a dose of a disputed stimulant-containing herb is not self-care.

Safety & contraindications

The safety story is dominated by the ephedrine-type alkaloids. The sympathomimetic risks of the root alkaloid fraction are those of pseudoephedrine itself: raised blood pressure and heart rate, CNS stimulation, and raised blood glucose (Jiménez-Ferrer et al., Plants 2025). On February 11, 2004, the U.S. FDA issued a final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk of illness or injury (FDA final rule, 69 FR 6787). Effective April 12, 2004, the rule prohibited the sale of such supplements, with sida cordifolia explicitly named among the covered botanicals (Federal Register/DEA summary). To be precise about what that means: the rule banned the marketing of dietary supplements containing ephedrine alkaloids; it did not ban the plant in every context. But the unreasonable-risk finding is real, and I treat bala products with corresponding caution.

Practically: anyone with a heart condition, high blood pressure, or diabetes, anyone taking stimulant or decongestant medicines, and anyone who is pregnant or breastfeeding should not use bala-containing products without a qualified practitioner's assessment of the specific product. A note for competitive athletes: WADA's Prohibited List (S6 stimulants, prohibited in-competition) names ephedrine and pseudoephedrine as specified stimulants, so a bala product with real stimulant-alkaloid content is a doping risk for tested athletes (WADA Prohibited List, S6). The one animal study noted low acute toxicity of a leaf extract in mice (Franzotti et al., J Ethnopharmacol 2000): but that says nothing about the safety of root preparations rich in stimulant alkaloids, and I do not want anyone drawing comfort from it.

FAQs

What is bala?

Bala is Sida cordifolia L., a mallow-family herb used in Ayurveda as a strengthening tonic (rasayana) for respiratory, inflammatory, and neurological complaints (Tailor 2026:_A_Comprehensive_Review_of_its_Ethnobotany,_Phytochemistry,_and_Pharmacology.pdf)). Its roots contain stimulant ephedrine-type alkaloids, though the exact ephedrine content is disputed (Jiménez-Ferrer et al., Plants 2025). My short version: classical tonic, stimulant chemistry, thin human evidence.

Is there any clinical evidence for bala?

Very little, and none for bala as a single herb. The one identifiable randomized trial (Patel et al., 2022, in diabetic sensory polyneuropathy) combined bala with Phyllanthus niruri, so its result cannot be attributed to bala alone. Separately, a 2025 review tabulates one poorly detailed knee-osteoarthritis study of an Ayurvedic medicated-milk preparation, but the review does not report the trial's design, the primary paper is not identified, and no regimen or result can be stated (Jiménez-Ferrer et al., Plants 2025). Everything else is animal or laboratory work. I would not call that a clinical evidence base.

Why was bala banned in supplements?

In 2004 the FDA declared dietary supplements containing ephedrine alkaloids adulterated as presenting an unreasonable risk of illness or injury, effective April 12, 2004, and sida cordifolia was explicitly named among the covered botanicals (FDA final rule, 69 FR 6787; Federal Register/DEA summary). Strictly, the rule targeted supplements containing ephedrine alkaloids, not the plant in all forms, but the safety signal behind it is the part I take seriously.

Is bala safe to take?

Its reported stimulant alkaloids carry the sympathomimetic risks of pseudoephedrine: raised blood pressure and heart rate, and nervous-system stimulation (Jiménez-Ferrer et al., Plants 2025). Given the FDA's unreasonable-risk finding for ephedrine-alkaloid supplements, bala products should be treated with the same caution, especially with heart conditions, hypertension, diabetes, or during pregnancy. I would not self-experiment with this one.

Can bala be used for arthritis?

The single human data point is one small, poorly detailed trial of an Ayurvedic milk preparation in knee-osteoarthritis patients, tabulated in a review without design details or an identifiable primary paper (Jiménez-Ferrer et al., Plants 2025). That is not a basis for self-treatment. Discuss evidence-based options with a clinician.

Voices

Classical

Bala's reputation as a strength herb is written into the classical groupings themselves. A 2024 review in the Journal of Ayurveda and Integrated Medical Sciences (Maurya Bhavna, Mishra H.S., and Agarwal A.K.) surveys bala's place across the Samhita texts and reports that the Charaka Samhita lists bala in three of the great drug-grouping lists (mahakashaya) of Sutra Sthana chapter 4: Balya (strength-promoting), Brimhaniya (bulk-promoting and nourishing), and Prajasthapana (conception-supporting). The review records the epithet "Sangrahik Balya Vataharanam": astringent and binding, strength-giving, and pacifying vata (Maurya Bhavna et al., J-AIM 2024).

In the Sushruta Samhita, the same review places bala in the Vata Samshamana Varga and the Madhur Varga, and names Sushruta's bala formulations for vata disorders: Bala Taila in hemiplegia (SS.Ci.5.19), Sahasrapaka or Satapaka Bala Taila for vatarakta (CS.Ci.29.119-20), and the Bala Rasayana chapter (SS.Ci.27.10). Vagbhata is reported to include bala in the Madhyam Panchamoola, and the review notes the Ashtanga Hridayam's prescription of ghee cooked with bala and milk for wasting (AH.Ci.5.14-15). (Maurya Bhavna et al., J-AIM 2024)

Modern

The modern literature gives bala a modest, carefully framed voice. In a 2025 experimental study of S. cordifolia in Huntington's-disease models (nematode and mouse-cell), the authors note that the herb "is one of the most commonly used herbs in Ayurveda to treat diseases of the nervous system," and describe a case study of one patient with early-onset Huntington's disease in which whole-system Ayurvedic treatment, with S. cordifolia as an important component, led to reduced involuntary movements and improved balance and gait (cited as Malavika and Savitha, 2022). One patient is an anecdote, not evidence; it is included here because it is a published case report, not a marketing story. (Sida cordifolia and ER stress in Huntington's disease models)

A randomized, partly double-blinded, placebo-controlled trial in the Journal of Ayurveda and Integrative Medicine (Patel et al., 2022, NCT02107469) tested an S. cordifolia root decoction (7 g, twice daily) co-administered with Phyllanthus niruri whole-plant powder (3 g, three times daily), and aqueous-alcoholic extracts of the same pair, in 90 patients with diabetic sensory polyneuropathy. Both herbal forms beat placebo on neuropathic symptom scores, but because the trial used a two-herb combination, the result says nothing about bala alone. That trial design is the strongest shape of modern evidence on a bala-containing regimen I found. It still tells you nothing about the traditional tonic claims, which were never tested in it. (J-AIM 13(2022))

Sources

The genus-level picture, including the chemistry and the tabulated human study, comes from Jiménez-Ferrer and colleagues' 2025 review, "Sida L.: Ethnobotany, Pharmacology, and Phytochemistry: A Review," in Plants 14(19):3115: mdpi.com. The caution that ephedrine's presence in the plant is scientifically disputed comes from Tailor's 2026 comprehensive review in the Mathews Journal of Pharmaceutical Science: mathewsopenaccess.com):_A_Comprehensive_Review_of_its_Ethnobotany,_Phytochemistry,_and_Pharmacology.pdf. The animal work on inflammation and pain is Franzotti et al.'s 2000 Journal of Ethnopharmacology study of aqueous leaf extract (400 mg/kg, oral), PMID 10967481: unboundmedicine.com. The regulatory record is the FDA's February 2004 final rule declaring ephedrine-alkaloid dietary supplements adulterated, PMID 14968803: PubMed · PMID 14968803, with sida cordifolia named among the covered botanicals in the Federal Register/DEA summary: federalregister.gov. The classical attributions are surveyed in Maurya Bhavna, Mishra H.S., and Agarwal A.K., "Validation of classical pharmacology of Sida cordifolia Linn. (Bala) through reverse pharmacology," Journal of Ayurveda and Integrated Medical Sciences 9(2), February 2024, DOI 10.21760/jaims.9.2.32: jaims.in. The Huntington's-disease case report is cited as reported in the PMC experimental study of S. cordifolia in HD models: PMC · PMC11961963. The diabetic sensory polyneuropathy trial is Patel M.V. et al., Journal of Ayurveda and Integrative Medicine 13(2022) 100619: wisdomlib.org. The WADA Prohibited List names ephedrine and pseudoephedrine as specified stimulants prohibited in-competition (S6): wada-ama.org.

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.